Investigation of the Combination Anticancer Effects of Olaparib and SAHA in Small Cell Lung Cancer
碩士 === 國立交通大學 === 分子醫學與生物工程研究所 === 107 === Lung cancer is the leading cause of cancer deaths. It can be divided into two types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Among them, SCLC has the characteristics of rapid growth, early metastasis, high aggressive and intens...
Main Authors: | Chung, Hui-Yu, 鍾惠伃 |
---|---|
Other Authors: | Liang, Mei-Chih |
Format: | Others |
Language: | en_US |
Published: |
2019
|
Online Access: | http://ndltd.ncl.edu.tw/handle/aw8zcu |
Similar Items
-
The anticancer activity of olaparib in small cell lung cancer
by: Chang, Ying-Feng, et al.
Published: (2016) -
Melatonin Enhances the Antitumor Activity of the HDAC Inhibitor SAHA in Small Cell Lung Cancer
by: Li, Yan-Liang, et al.
Published: (2019) -
Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
by: Wu M, et al.
Published: (2018-12-01) -
Investigation on the anticancer effects of 2-deoxyglucose combined with cisplatin/etoposide in small cell lung cancer
by: Peng, Nai-En, et al.
Published: (2019) -
Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
by: Li, S., et al.
Published: (2022)